Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Inadvertent Rare Use of Plasma Exchange in the Treatment of Upshaw-Shulman Syndrome

ASFA 2024

American Society for Aspheresis

Las Vegas, NV April 17-19, 2024

Poster presentation: Inadvertent Rare Use of Plasma Exchange in the Treatment of Upshaw-Shulman Syndrome

Authors: Joseph C, Wong ECC, Darbari D, Jacquot C, Mo Y, Makuria A, Webb J

Specialty: Oncology, Coagulation, Hematology

Related content

Conference Presentation
The First Report Of The American Society For Apheresis Focal Segmental Glomerulosclerosis Multi-Institutional Registry
Conference Presentation
Variability in total plasma volume calculations for patients with potentially challenging clinical conditions: a vignette-based investigation by the american society for apheresis allied health research subcommittee
Test FAQ
ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
Conference Presentation
Using GP1bM Activity (VWF:GPIbM) Versus Ristocetin Cofactor Activity (VWF:RCo) in von Willebrand Factor Panels
Conference Presentation
The First Report of the American Society for Apheresis Thrombotic Thrombocytopenic Purpura Multi-institutional Registry: 2019-2020

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.